Washout Duration of Prostaglandin Analogues: A Systematic Review and Meta-analysis

被引:20
作者
Diaconita, Vlad [1 ,2 ]
Quinn, Matthew [2 ,3 ]
Jamal, Dania [4 ]
Dishan, Brad [5 ]
Malvankar-Mehta, Monali S. [1 ,6 ]
Hutnik, Cindy [1 ,2 ]
机构
[1] Ivey Eye Inst, London, ON, Canada
[2] Western Univ, Schulich Sch Med & Dent, London, ON, Canada
[3] Queens Univ, Dept Ophthalmol, Kingston, ON, Canada
[4] King Abdulaziz Univ, Jeddah, Saudi Arabia
[5] St Josephs Hlth Care, London, ON, Canada
[6] Western Univ, Schulich Sch Med & Dent, Dept Epidemiol & Biostat, London, ON, Canada
关键词
OPEN-ANGLE GLAUCOMA; GEL-FORMING SOLUTION; INTRAOCULAR-PRESSURE; LATANOPROST; 0.005-PERCENT; OCULAR HYPERTENSION; BRIMONIDINE; 0.2-PERCENT; COMPARING LATANOPROST; TIMOLOL; EFFICACY; BIMATOPROST;
D O I
10.1155/2018/3190684
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Topic. Prostaglandin analogues (PGAs) are first-line medical therapy for primary open angle glaucoma (POAG) and ocular hypertension (OHT). Intraocular pressure (IOP) lowering effects in full responders are known to be 25-33% for this class; however, partial responders and nonresponders do exist. In clinical trials or prospective series, discontinuation and washout of PGAs is necessary to evaluate true change in IOP from novel surgeries and medical therapies. Clinical Relevance. To identify all relevant papers with pertinent data on washout of PGAs and quantify the duration and long-term effect of reported PGA washout periods in glaucoma and OHT patients. Methods. A systematic review and meta-analysis was conducted to investigate the long-term effects on IOP after discontinuation of topical PGAs POAG and OHT patients.) The main search was conducted in MEDLINE/PubMed, EMBASE, Cochrane Library, CINAHL, Web of Science, and BIOSIS Previews and conference proceedings. Results. 1055 papers were identified, 548 were independently screened by two physicians., and 56 papers were analyzed for washout durations.) The mean washout was found to be 4.56 weeks (+/- 1.25), with the mode and median being 5 weeks. Five studies were analyzed as randomized control trials in which latanoprost was discontinued for 4 weeks prior to restarting another intraocular pressure-lowering drug. Meta-analysis revealed a 4-week discontinuation of latanoprost, on average, subjects returned to their baseline IOP. Conclusion. A significant IOP-lowering effect of latanoprost was not observed beyond 4 weeks, suggesting this may be an appropriate washout period for latanoprost. We could not identify appropriate washout periods for either travoprost or bimatoprost, although a majority of articles had 4-week washout durations for the two drugs. Despite the widespread use of this class of medication, there is a paucity of literature on the effects of PGA washout in patients that are treatment naive to other topical medications.
引用
收藏
页数:8
相关论文
共 28 条
  • [1] PHXA34, A NEW POTENT OCULAR HYPOTENSIVE DRUG - A STUDY ON DOSE-RESPONSE RELATIONSHIP AND ON AQUEOUS-HUMOR DYNAMICS IN HEALTHY-VOLUNTEERS
    ALM, A
    VILLUMSEN, J
    [J]. ARCHIVES OF OPHTHALMOLOGY, 1991, 109 (11) : 1564 - 1568
  • [2] Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning - A comparison with timolol
    Alm, A
    Stjernschantz, J
    Widengard, I
    Linden, C
    Soderstrom, M
    Nilsson, SE
    Fristrom, B
    Lindblom, B
    Heijl, A
    Gundersen, KG
    Ehinger, B
    Holmin, C
    BengtssonStigmar, E
    Aasved, H
    Jangard, P
    Ringvold, A
    Vegge, T
    Halseide, R
    LundAndersen, H
    Flesner, P
    Thygesen, J
    Airaksinen, J
    Tuulonen, A
    [J]. OPHTHALMOLOGY, 1995, 102 (12) : 1743 - 1752
  • [3] A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension
    Aung, T
    Chew, PTK
    Yip, CC
    Chan, YH
    See, JLS
    Khng, CC
    Hoh, ST
    Ng, LH
    Lee, HM
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2001, 131 (05) : 636 - 642
  • [4] Latanoprost, a prostaglandin analog, for glaucoma therapy - Efficacy and safety after 1 year of treatment in 198 patients
    Camras, CB
    Alm, A
    Watson, P
    Stjernschantz, J
    Aasved, H
    Jangard, P
    LundAndersen, H
    Flesner, P
    Soderstrom, M
    Ehinger, B
    Holmin, C
    BengtssonStigmar, E
    Heijl, A
    Gundersen, KG
    Airaksinen, J
    Tuulonen, A
    Halseide, R
    Lindblom, B
    Ringvold, A
    Vegge, T
    Linden, C
    Nilsson, SE
    Fristrom, B
    Widengard, I
    Thygesen, J
    Green, F
    Valenzuela, F
    Potts, M
    Spencer, I
    Coakes, R
    Reynolds, P
    Mills, B
    Chatterjee, A
    Nagasubramanian, S
    Roxburgh, S
    Sanders, R
    Bailey, M
    Whyte, IF
    Vernon, S
    Sloper, M
    Murray, S
    Davey, C
    HickmanCasey, J
    Longstaff, S
    Currie, Z
    Wishart, P
    Austin, M
    Birch, M
    Elkington, A
    Luff, A
    [J]. OPHTHALMOLOGY, 1996, 103 (11) : 1916 - 1924
  • [5] Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma - A six-month, masked, multicenter trial in the United States
    Camras, CB
    Cioffi, GA
    VanBuskirk, EM
    Fraser, J
    Stewart, WC
    Stewart, JA
    Lustgarten, J
    Schumer, RA
    Podos, SM
    Arroyo, M
    Nitzberg, S
    Ritch, R
    Abundo, G
    Caronia, R
    Liebmann, J
    Steinberger, D
    Krupin, T
    Rosenberg, LF
    Ruderman, JM
    Clarkson, K
    Weinreb, RN
    Ochabsi, R
    Sherwood, M
    Smith, MF
    Stokes, DW
    Zam, ZS
    Wilensky, J
    Hillman, D
    Kaplan, B
    Gates, V
    Nail, C
    Zimmerman, T
    Fechtner, R
    Fenton, R
    Fenton, J
    Higginbotham, EJ
    Johnson, AT
    PollackRundle, CJ
    Weiss, E
    Yablonski, ME
    Tannenbaum, MH
    Ibrahim, F
    Ohia, E
    Neely, D
    Minckler, D
    Heuer, D
    Lee, P
    Padea, M
    Kaufman, PL
    Heatley, GA
    [J]. OPHTHALMOLOGY, 1996, 103 (01) : 138 - 147
  • [6] Canadian Ophthalmological Society Glaucoma Clinical Practice Guideline Expert Committee, 2009, Can J Ophthalmol, V44 Suppl 1, pS7, DOI 10.3129/cjo44s1
  • [7] The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions
    Downs, SH
    Black, N
    [J]. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 1998, 52 (06) : 377 - 384
  • [8] Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated Intraocular pressure
    Dubiner, HB
    Sircy, MD
    Landry, T
    Bergamini, MV
    Silver, LH
    Turner, FD
    Robertson, S
    Andrew, RM
    Weiner, A
    Przydryga, J
    [J]. CLINICAL THERAPEUTICS, 2004, 26 (01) : 84 - 91
  • [9] Bias in meta-analysis detected by a simple, graphical test
    Egger, M
    Smith, GD
    Schneider, M
    Minder, C
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109): : 629 - 634
  • [10] Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension
    Gandolfi, S
    Simmons, ST
    Sturm, R
    Chen, KK
    Vandenburgh, AM
    [J]. ADVANCES IN THERAPY, 2001, 18 (03) : 110 - 121